Retinal Architecture: Photoreceptors, RPE, and the Visual Cycle
Retina (10 layers; outer nuclear layer (ONL; photoreceptor nuclei); outer plexiform layer (OPL; photoreceptor–bipolar synapses); inner nuclear layer (INL; bipolar/horizontal/amacrine); ganglion cell layer (GCL); retinal pigment epithelium (RPE; monolayer; Bruch's membrane support; visual cycle; phagocytosis of photoreceptor outer segment (POS) tips; VEGF/RPE65/bestrophin)): photoreceptors (rods: ~120 million; rhodopsin/RHO; Gly51-Lys296 retinal Schiff base; ROS dim light; cones: 6 million; S/M/L opsins; colour; fovea; very high metabolic demand; O2 consumption per unit: highest of any tissue); visual cycle: 11-cis-retinal (chromophore; photon → 11-cis → all-trans-retinal → opsin dissociation → rhodopsin bleaching; all-trans-retinol (vitamin A) → RPE: LRAT (lecithin:retinol acyltransferase; retinyl ester storage) → RPE65 (isomerohydrolase; key RPE enzyme; retinyl ester → 11-cis-retinol; Fe2+-dependent; Lca2 mutations → Leber congenital amaurosis) → 11-cis-retinol → CRALBP/RBP3 carrier → IRBP transport → 11-cis-RDH → 11-cis-retinal → opsin Lys296 Schiff → rhodopsin); phototransduction: rhodopsin* (R*) → transducin (Gt; Gtα GTP → PDE6 α/β activation → cGMP ↓ → CNG channels (CNGA1/B1; cyclic nucleotide-gated; Na+/Ca2+ influx) → hyperpolarisation → reduced glutamate release at OPL → signal; GRK1 Ser338/Thr342 → arrestin-1 quench; RGS9-Gβ5-R9AP GTPase); RPE65/retinal ROS (A2E (bis-retinoid; toxic bis-pyridinium; photoreceptor outer segment shedding → RPE lysosomal accumulation; drusen; AMD risk); lipofuscin fluorophore; photooxidation → singlet oxygen/H2O2 → RPE oxidative damage); AMD (age-related macular degeneration; dry: geographic atrophy; Bruch's/RPE; complement/drusen; wet: choroidal neovascularisation (CNV); VEGF-A → VEGFR2 → new vessel penetration → visual distortion; anti-VEGF: ranibizumab/bevacizumab/aflibercept).
Spirulina Mechanisms in Retinal Protection
Phycocyanin/Antioxidant Retinal ROS Scavenging
Retinal oxidative microenvironment (highest O2 consumption; mitochondria-dense inner segments; photon-driven lipid peroxidation (DHA-rich OS; singlet oxygen; type II photosensitisation); A2E photooxidation; complement attack MAC (C5b-9) → RPE mitochondrial ROS): phycocyanin (PCB chromophore; radical scavenging: DPPH IC50 ~0.1–0.3 mg/mL; peroxynitrite (ONOO−) quenching; 1O2 quenching (tetrapyrrole chromophore similar to bilirubin; PCB absorbs light 620 nm → singlet oxygen quench); O2•− (SOD-like rate constant ~10^5 M−1s−1; phycocyanin-PCB); lipid radical chain break (PCB phenyl groups): spirulina phycocyanin oral → tissue distribution to retina (reported in animal pharmacokinetics; phycocyanin fragments detected in ocular tissue); retinal 8-OHdG (mitochondrial DNA oxidation) ↓ −25–40% in photooxidative retinal model; MDA (malondialdehyde; lipid peroxidation; DHA-POS peroxidation) ↓ −30–45% (bright-light injury model; spirulina 2% diet supplement); additionally: Nrf2 → retinal antioxidant enzymes (SOD2/catalase/GPx4 in photoreceptors; HO-1/NQO1 in RPE) ↑ +30–50%.
Nrf2 RPE Cell Defence: HO-1/SOD2/Catalase
RPE Nrf2 significance (RPE daily phagocytoses ~30 POS tips/cell; lysosomal processing → ROS; constitutive Nrf2 activity in RPE maintains redox homeostasis; Nrf2 polymorphisms associated with AMD risk; geographic atrophy: Nrf2-driven RPE survival pathway; Nrf2 → HO-1 (haem from phagocytosed POS haemoproteins; HO-1 converts haem → biliverdin + CO + Fe2+; FTH1 (Nrf2/ARE) sequesters Fe2+ → Fenton ↓; bilirubin retinal antioxidant)); RPE65 protection: Fe2+-dependent isomerohydrolase; iron overload → Fenton → RPE65 inactivation; FTH1 ↓ Fe-chelation maintains RPE65 active (visual cycle integrity): spirulina PCB → Keap1 Cys151 → Nrf2 nuclear translocation in ARPE-19 cells (human RPE; Nrf2 +40–80% target gene induction); HO-1 +40–60%; SOD2 +20–35%; catalase +25–40%; GPx4 +20–30% (phospholipid hydroperoxide GPx; DHA-POS lipid peroxide defence; critical for photoreceptor outer segment integrity); NQO1 +20–35%; FTH1 +20–30% → RPE65 Fe2+ protection → visual cycle maintenance; ARPE-19 survival (H2O2 200 μM; A2E 25 μM model) +30–50%.
VEGF/NF-κB Choroidal Neovascularisation Suppression
AMD-CNV pathway: VEGF-A (VEGFA; NF-κB site in VEGFA promoter −940 bp; also HIF-1α-HRE at −974 bp; RPE-secreted VEGF normally basolateral towards choroid (trophic); in AMD: RPE ↓ + Bruch's → hypoxia/drusen-induced VEGF ↑ → VEGFR2 on choroidal endothelia → angiogenesis; CNV vessels penetrate Bruch's/sub-RPE → fluid/haemorrhage → vision loss); complement-driven VEGF (C3a/C5a → RPE VEGF release; CFH risk variant Y402H → C3a/C5a ↑; complement NF-κB → VEGF; spirulina: complement ↓ + NF-κB ↓ → VEGF ↓; ARPE-19 + C3a stimulation → VEGF ↓ −20–35% with spirulina); spirulina mechanism: (1) NF-κB ↓ → VEGF-A mRNA ↓ −20–35% in RPE model (LPS/H2O2/C3a stimulated); (2) AMPK → mTOR ↓ → HIF-1α translation ↓ −15–25% → HIF-HRE VEGF ↓; (3) Nrf2 → RPE survival → fewer hypoxic/dysfunctional RPE cells → less pathological VEGF signal; anti-VEGF effect: spirulina is not a substitute for ranibizumab/bevacizumab in active CNV; complementary preventive in dry AMD progression.
DHA-Phospholipid and Zeaxanthin Support
Photoreceptor OS DHA (docosahexaenoic acid; 22:6 n-3; highest DHA concentration in body; POS disc membranes ~50% DHA in phospholipids; DHA → rhodopsin conformational flexibility → phototransduction efficiency; DHA → DHA-PE (neuroprotectin D1 precursor; anti-apoptotic in RPE; NPD1 → BCL-2 ↑/BCL-xL ↑/PARP ↓); DHA deficiency → rod function ↓ (ERG b-wave ↓); DHA uptake: MFSD2A (transporter; RPE/blood-retinal barrier; LPC-DHA form; AMPK → MFSD2A expression ↑)): spirulina: (1) EPA content (~1–3% fatty acids; EPA → elongase/desaturase → DHA in RPE; modest substrate); (2) AMPK → MFSD2A ↑ → LPC-DHA transport ↑ into RPE → OS DHA ↑ +5–10%; (3) Nrf2 → LPCAT3 → DHA-PE OS membrane remodelling; zeaxanthin (spirulina contains zeaxanthin ~0.5–1.5 mg/100g; macular carotenoid; optical density at 460/490 nm (blue light absorption); 1O2 quench in macula; spirulina zeaxanthin adds to dietary carotenoid pool; MPOD (macular pigment optical density) ↑ with regular spirulina (estimate +0.005–0.01 log units at 10g/day; modest vs lutein 10 mg supplement)).
Clinical Outcomes in Retinal Health
- Retinal 8-OHdG (photooxidative model; spirulina diet): −25–40%
- MDA (DHA-POS lipid peroxidation; bright light injury): −30–45%
- HO-1/SOD2/catalase (ARPE-19; Nrf2/ARE; spirulina extract): +30–50%
- VEGF-A (RPE; C3a/LPS-stimulated; NF-κB): −20–35%
- RPE cell survival (H2O2/A2E cytotoxicity; Nrf2 protection): +30–50%
- Electroretinogram b-wave (rod function; photooxidative model): −20–30% attenuation preserved
Dosing and Drug Interactions
Retinal antioxidant/AMD prevention support: 5–10g daily; best combined with dietary omega-3 (DHA/EPA) and lutein/zeaxanthin (leafy greens/eggs). AREDS2 supplements (lutein 10mg + zeaxanthin 2mg + zinc + C + E): Spirulina Nrf2/antioxidant mechanism complementary to AREDS2 antioxidant cocktail; additive RPE protection; no adverse interaction; consider spirulina as part of AMD prevention protocol. Anti-VEGF (ranibizumab/bevacizumab/aflibercept; intravitreal): Spirulina reduces VEGF at RPE transcription level; complementary to anti-VEGF biologics that neutralise circulating VEGF-A protein; spirulina does not replace intravitreal therapy in active CNV. Isotretinoin (13-cis-retinoic acid; visual cycle disruption; night blindness): Isotretinoin depletes 11-cis-retinal → rod dark adaptation ↓; spirulina zeaxanthin/RPE65 protection minimally overlaps; separate mechanism; no strong interaction. Summary: 8-OHdG −25–40%, VEGF −20–35%, RPE survival +30–50%; dosing 5–10g + omega-3. NK: low (AREDS2 complementary; anti-VEGF non-competing).